CSIMarket
 
Neoleukin Therapeutics Inc   (NLTX)
Other Ticker:  
 
 
Price: $3.4900 $0.05 1.453%
Day's High: $3.59 Week Perf: 5.76 %
Day's Low: $ 3.42 30 Day Perf: 6.08 %
Volume (M): 113 52 Wk High: $ 4.70
Volume (M$): $ 395 52 Wk Avg: $3.75
Open: $3.45 52 Wk Low: $3.05



 Market Capitalization (Millions $) 39
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Neoleukin Therapeutics Inc
Neoleukin Therapeutics Inc is a biopharmaceutical company specializing in the development of immunotherapies for the treatment of various diseases. The company focuses on engineering synthetic proteins that can activate the immune system or mimic natural proteins to regulate it.

Using a proprietary computational platform, Neoleukin designs and develops novel protein therapeutics with improved properties and capabilities compared to existing treatments. These therapeutic candidates are being developed to target a range of diseases, including autoimmune disorders, cancer, and metabolic diseases.

Neoleukin's approach involves modifying the structure of proteins to enhance their potency, stability, and selectivity, allowing for more effective and precise treatments. By harnessing the body's natural defense mechanisms, the company aims to provide safer and more targeted therapies with fewer side effects.

The company is committed to advancing scientific research and collaborating with other experts in the field to accelerate the development of innovative therapies. Neoleukin Therapeutics Inc is at the forefront of the biopharmaceutical industry, striving to make a significant impact in the field of immunotherapy for the benefit of patients worldwide.


   Company Address: 188 East Blaine Street Seattle 98102 WA
   Company Phone Number: 245-0312   Stock Exchange / Ticker: NASDAQ NLTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neoleukin Therapeutics Inc

Neoleukin Therapeutics Targets Financial Growth with Strategic Initiatives

Neoleukin Therapeutics takes proactive steps to enhance compliance and shareholder value
Seattle-based biopharmaceutical company, Neoleukin Therapeutics, Inc. (NASDAQ: NLTX), has recently announced its decision to initiate a reverse stock split in a bid to regain compliance with Nasdaq's minimum bid price requirement. The move comes as part of Neoleukin's strategic plan to position itself for future growth and advance its unique de novo protein therapeutics designed using sophisticated computational methods.
Having reported an operating deficit of $-5.569 million for the fiscal three months closing on September 30, 2023, the company is keen on improving its financial performance. Regulatory compliance plays a crucial role in maintaining investor confidence, and Neoleukin's decision to consolidate its outstanding shares of common stock at a ratio of 1-for-5 is aimed at meeting the minimum bid price requirement while preserving shareholder value.

Shares

Neoleukin Therapeutics Initiates Reverse Stock Split to Pave the Path for Future Success

Published Fri, Sep 22 2023 12:00 PM UTC



Seattle-based biopharmaceutical company, Neoleukin Therapeutics, Inc. (NASDAQ: NLTX), has recently announced its decision to initiate a reverse stock split, in a bid to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The move comes as part of Neoleukin's strategic plan to position itself for future growth and advance its unique de ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com